Cargando…
Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70
Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919351/ https://www.ncbi.nlm.nih.gov/pubmed/7525524 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x |
_version_ | 1783317606362513408 |
---|---|
author | Kato, Nobuyuki Nakazawa, Takahide Ootsuyama, Yuko Sugiyama, Kazuo Ohkoshi, Showgo Shimotohno, Kunitada |
author_facet | Kato, Nobuyuki Nakazawa, Takahide Ootsuyama, Yuko Sugiyama, Kazuo Ohkoshi, Showgo Shimotohno, Kunitada |
author_sort | Kato, Nobuyuki |
collection | PubMed |
description | Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or specific for the homologous virus isolate, we examined the reactivities of sera from 53 patients with chronic hepatitis or hepatocellular carcinoma/liver cirrhosis against two different HVR1 peptides (HVR11‐1 and HVR1 Y‐l) derived from patient I with sporadic acute hepatitis and an asymptomatic carrier Y, respectively, using our original assay system for the detection of anti‐HVR1 antibody. All patients examined had a history of blood transfusion. Most sera showed no reactivity with either HVR1 1‐1 or HVR1 Y‐l peptide. Only seven and fourteen serum samples reacted significantly, although weakly, with HVR1 1‐1 and HVR1 Y‐l peptides, respectively, compared with the serum from patient I or asymptomatic carrier Y. The blood transfusions of most reactive cases had occurred more than thirty years earlier. Six cases reacted with both HVR1 1‐1 and HVR1 Y‐l peptides, but further analysis revealed that only three cases reacted weakly with the peptide for either epitope I or II, identified within HVR11‐1, These results indicate that the B‐cell epitopes within HVR1 are fairly specific for the homologous virus isolate, and this may represent a serious difficulty in the development of a vaccine against HCV. |
format | Online Article Text |
id | pubmed-5919351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59193512018-05-11 Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 Kato, Nobuyuki Nakazawa, Takahide Ootsuyama, Yuko Sugiyama, Kazuo Ohkoshi, Showgo Shimotohno, Kunitada Jpn J Cancer Res Article Hypervariable region 1 (HVR1), located in the N‐terminal region of a putative second envelope glycoprotein (gp70) of hepatitis C virus (HCV), contains immunological B‐cell epitopes which might be neutralizing epitopes. To clarify whether B‐cell epitopes within HVR1 are common among virus isolates or specific for the homologous virus isolate, we examined the reactivities of sera from 53 patients with chronic hepatitis or hepatocellular carcinoma/liver cirrhosis against two different HVR1 peptides (HVR11‐1 and HVR1 Y‐l) derived from patient I with sporadic acute hepatitis and an asymptomatic carrier Y, respectively, using our original assay system for the detection of anti‐HVR1 antibody. All patients examined had a history of blood transfusion. Most sera showed no reactivity with either HVR1 1‐1 or HVR1 Y‐l peptide. Only seven and fourteen serum samples reacted significantly, although weakly, with HVR1 1‐1 and HVR1 Y‐l peptides, respectively, compared with the serum from patient I or asymptomatic carrier Y. The blood transfusions of most reactive cases had occurred more than thirty years earlier. Six cases reacted with both HVR1 1‐1 and HVR1 Y‐l peptides, but further analysis revealed that only three cases reacted weakly with the peptide for either epitope I or II, identified within HVR11‐1, These results indicate that the B‐cell epitopes within HVR1 are fairly specific for the homologous virus isolate, and this may represent a serious difficulty in the development of a vaccine against HCV. Blackwell Publishing Ltd 1994-10 /pmc/articles/PMC5919351/ /pubmed/7525524 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x Text en |
spellingShingle | Article Kato, Nobuyuki Nakazawa, Takahide Ootsuyama, Yuko Sugiyama, Kazuo Ohkoshi, Showgo Shimotohno, Kunitada Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title | Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title_full | Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title_fullStr | Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title_full_unstemmed | Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title_short | Virus Isolate‐specific Antibodies against Hypervariable Region 1 of the Hepatitis C Virus Second Envelope Protein, gp70 |
title_sort | virus isolate‐specific antibodies against hypervariable region 1 of the hepatitis c virus second envelope protein, gp70 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919351/ https://www.ncbi.nlm.nih.gov/pubmed/7525524 http://dx.doi.org/10.1111/j.1349-7006.1994.tb02894.x |
work_keys_str_mv | AT katonobuyuki virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 AT nakazawatakahide virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 AT ootsuyamayuko virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 AT sugiyamakazuo virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 AT ohkoshishowgo virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 AT shimotohnokunitada virusisolatespecificantibodiesagainsthypervariableregion1ofthehepatitiscvirussecondenvelopeproteingp70 |